Stock Events

Stock Events

Oncotelic Therapeutics 

$0.04
4
+$0+3.59% Thursday 19:58

Statistics

Day High
0.05
Day Low
0.04
52W High
0.11
52W Low
0.02
Volume
230,700
Avg. Volume
296,696
Mkt Cap
17.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20AprExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-9.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OTLC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a leading pharmaceutical company that competes with Oncotelic in the oncology sector, particularly in developing treatments for various cancers.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including cancer, directly competing with Oncotelic's focus.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company with a significant presence in oncology, making it a competitor in developing cancer therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis is a healthcare company that operates globally, focusing on innovative medicines, including oncology, which pits it against Oncotelic Therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a pioneer in healthcare, with a strong emphasis on oncology, competing in the research and development of cancer treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca specializes in the discovery, development, and commercialization of prescription medicines, including those for cancer, competing with Oncotelic in the oncology market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, including oncology.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology company that develops innovative human therapeutics, with a focus on oncology treatments, competing with Oncotelic in cancer therapy development.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company is a global healthcare leader that manufactures medicines in several segments, including cancer, making it a competitor to Oncotelic.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes medicines for the treatment of serious medical conditions, including oncology, competing with Oncotelic in the field of cancer treatment.

About

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Show more...
CEO
Dr. Vuong Trieu Ph.D.
Employees
26
Country
US
ISIN
US6283411097

Listings

OTC Link
US
OTLC

0 Comments

Share your thoughts

FAQ

What is Oncotelic Therapeutics stock price today?▼
The current price of OTLC is $0.04 USD — it has increased by +3.59% in the past 24 hours. Watch Oncotelic Therapeutics stock price performance more closely on the chart.
What is Oncotelic Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncotelic Therapeutics stocks are traded under the ticker OTLC.
Is Oncotelic Therapeutics stock price growing?▼
OTLC stock has fallen by -2.5% compared to the previous week, the month change is a -2.5% fall, over the last year Oncotelic Therapeutics has showed a -33.9% decrease.
What is Oncotelic Therapeutics market cap?▼
Today Oncotelic Therapeutics has the market capitalization of 17.19M
When is the next Oncotelic Therapeutics earnings date?▼
Oncotelic Therapeutics is going to release the next earnings report on April 20, 2026.
What is Oncotelic Therapeutics revenue for the last year?▼
Oncotelic Therapeutics revenue for the last year amounts to 0 USD.
What is Oncotelic Therapeutics net income for the last year?▼
OTLC net income for the last year is -9.05M USD.
How many employees does Oncotelic Therapeutics have?▼
As of April 04, 2026, the company has 26 employees.
In which sector is Oncotelic Therapeutics located?▼
Oncotelic Therapeutics operates in the Health Care sector.
When did Oncotelic Therapeutics complete a stock split?▼
Oncotelic Therapeutics has not had any recent stock splits.
Where is Oncotelic Therapeutics headquartered?▼
Oncotelic Therapeutics is headquartered in Agoura Hills, US.